FGF2 and central nervous system cancer: In SEG-1 cells and C6 glioma cells NUDT6 over-expression reduced cellular FGF2 immunoreactivity and inhibited cell cycle progression and proliferation [16,19], whereas in rat GH3 pituitary adenoma cells NUDT6 inhibited cell cycle progression and proliferation, but did not suppress FGF2 levels [5].